• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

费城儿童医院婴儿神经肌肉疾病测试(CHOP INTEND):测试的开发和可靠性。

The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability.

机构信息

Department of Physical Therapy, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.

出版信息

Neuromuscul Disord. 2010 Mar;20(3):155-61. doi: 10.1016/j.nmd.2009.11.014. Epub 2010 Jan 13.

DOI:10.1016/j.nmd.2009.11.014
PMID:20074952
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3260046/
Abstract

The motor skills of patients with spinal muscular atrophy, type I (SMA-I) are very limited. It is difficult to quantify the motor abilities of these patients and as a result there is currently no validated measure of motor function that can be utilized as an outcome measure in clinical trials of SMA-I. We have developed the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders ("CHOP INTEND") to evaluate the motor skills of patients with SMA-I. The test was developed following the evaluation of 26 infants with SMA-I mean age 11.5 months (1.4-37.9 months) with the Test of Infant Motor Performance and The Children's Hospital of Philadelphia Test of Strength in SMA, a newly devised motor assessment for SMA. Items for the CHOP INTEND were selected by an expert panel based on item mean and standard deviation, item frequency distribution, and Chronbach's alpha. Intra-rater reliability of the resulting test was established by test-retest of 9 infants with SMA-I over a 2 month period; Intraclass correlation coefficient (ICC) (3,1)=0.96. Interrater reliability was by video analysis of a mixed group of infants with neuromuscular disease by 4 evaluators; ICC (3,4)=0.98 and in a group of 8 typically developing infants by 5 evaluators ICC (3,5)=0.93. The face validity of the CHOP INTEND is supported by the use of an expert panel in item selection; however, further validation is needed. The CHOP INTEND is a reliable measure of motor skills in patients with SMA-I and neuromuscular disorders presenting in infancy.

摘要

脊髓性肌萎缩症 I 型(SMA-I)患者的运动技能非常有限。很难对这些患者的运动能力进行量化,因此目前尚无经过验证的运动功能测量方法可用于 SMA-I 的临床试验作为结果测量。我们开发了费城儿童医院婴儿神经肌肉疾病测试(“CHOP INTEND”)来评估 SMA-I 患者的运动技能。该测试是在对 26 名 SMA-I 患儿(平均年龄 11.5 个月(1.4-37.9 个月))进行评估后开发的,评估方法包括婴儿运动表现测试和费城儿童医院 SMA 力量测试,这是一种新设计的 SMA 运动评估方法。CHOP INTEND 的项目是由一个专家小组根据项目平均值和标准差、项目频率分布以及 Cronbach's alpha 选择的。9 名 SMA-I 患儿在 2 个月的时间内进行了测试-重测,从而确定了该测试的内部评估者可靠性;组内相关系数(ICC)(3,1)=0.96。通过由 4 名评估员对患有神经肌肉疾病的混合组婴儿进行视频分析,以及由 5 名评估员对 8 名正常发育婴儿进行视频分析,确定了该测试的外部评估者可靠性;ICC(3,4)=0.98 和 ICC(3,5)=0.93。CHOP INTEND 的表面效度得到了项目选择专家小组的使用支持;但是,还需要进一步验证。CHOP INTEND 是一种可靠的 SMA-I 患者和在婴儿期出现神经肌肉疾病患者运动技能的测量方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a2a5/3260046/372dabef650a/nihms297009f1a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a2a5/3260046/372dabef650a/nihms297009f1a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a2a5/3260046/372dabef650a/nihms297009f1a.jpg

相似文献

1
The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability.费城儿童医院婴儿神经肌肉疾病测试(CHOP INTEND):测试的开发和可靠性。
Neuromuscul Disord. 2010 Mar;20(3):155-61. doi: 10.1016/j.nmd.2009.11.014. Epub 2010 Jan 13.
2
Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND).费城儿童医院婴儿神经肌肉疾病测试(CHOP INTEND)的验证
Pediatr Phys Ther. 2011 Winter;23(4):322-6. doi: 10.1097/PEP.0b013e3182351f04.
3
Motor Function Test Reliability During the NeuroNEXT Spinal Muscular Atrophy Infant Biomarker Study.神经拓展脊髓性肌萎缩症婴儿生物标志物研究中运动功能测试的可靠性。
J Neuromuscul Dis. 2018;5(4):509-521. doi: 10.3233/JND-180327.
4
Commentary on "Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)".
Pediatr Phys Ther. 2011 Winter;23(4):327. doi: 10.1097/PEP.0b013e3182352896.
5
The test of infant motor performance: reliability in spinal muscular atrophy type I.婴儿运动能力测试:I型脊髓性肌萎缩症中的可靠性
Pediatr Phys Ther. 2008 Fall;20(3):242-6. doi: 10.1097/PEP.0b013e318181ae96.
6
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls.Risdiplam 治疗 1 型脊髓性肌萎缩症婴儿与历史对照。
N Engl J Med. 2021 Jul 29;385(5):427-435. doi: 10.1056/NEJMoa2102047.
7
Drug treatment for spinal muscular atrophy type I.I型脊髓性肌萎缩症的药物治疗
Cochrane Database Syst Rev. 2019 Dec 11;12(12):CD006281. doi: 10.1002/14651858.CD006281.pub5.
8
Brazilian version of the CHOP INTEND scale: cross-cultural adaptation and validation.巴西版 CHOP INTEND 量表:跨文化调适与验证。
Arq Neuropsiquiatr. 2023 Sep;81(9):816-824. doi: 10.1055/s-0043-1772832. Epub 2023 Oct 4.
9
Use of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) in X-Linked Myotubular Myopathy: Content Validity and Psychometric Performance.应用费城儿童医院婴儿神经肌肉疾病测试(CHOP INTEND)于 X 连锁肌小管肌病:内容效度和心理测量性能。
J Neuromuscul Dis. 2021;8(1):63-77. doi: 10.3233/JND-200479.
10
Evaluator Training and Reliability for SMA Global Nusinersen Trials1.脊髓性肌萎缩症全球依洛硫酸酯酶纳新酶临床试验 1 的评估者培训与可靠性
J Neuromuscul Dis. 2018;5(2):159-166. doi: 10.3233/JND-180301.

引用本文的文献

1
Eosinophilic Esophagitis in a 3-Year-Old Girl with Spinal Muscular Atrophy Type 1: The First Reported Case.一名1型脊髓性肌萎缩症3岁女童患嗜酸性食管炎:首例报告病例
Pediatr Rep. 2025 Jul 28;17(4):80. doi: 10.3390/pediatric17040080.
2
Correlation Between the Motor Outcomes and SMN2 and NAIP Gene Copy Numbers Among North Indian Children with Spinal Muscular Atrophy.北印度脊髓性肌萎缩症儿童运动结局与SMN2和NAIP基因拷贝数之间的相关性
Ann Indian Acad Neurol. 2025 Jul 1;28(4):579-584. doi: 10.4103/aian.aian_974_24. Epub 2025 Jun 3.
3
Rehabilitation management for patients with spinal muscular atrophy: a review.

本文引用的文献

1
Drug treatment for spinal muscular atrophy type I.I型脊髓性肌萎缩症的药物治疗
Cochrane Database Syst Rev. 2009 Jan 21(1):CD006281. doi: 10.1002/14651858.CD006281.pub2.
2
The test of infant motor performance: reliability in spinal muscular atrophy type I.婴儿运动能力测试:I型脊髓性肌萎缩症中的可靠性
Pediatr Phys Ther. 2008 Fall;20(3):242-6. doi: 10.1097/PEP.0b013e318181ae96.
3
Modern management of spinal muscular atrophy.脊髓性肌萎缩症的现代管理
脊髓性肌萎缩症患者的康复管理:综述
Orphanet J Rare Dis. 2025 Jul 10;20(1):352. doi: 10.1186/s13023-025-03888-w.
4
Risdiplam treatment following onasemnogene abeparvovec in individuals with spinal muscular atrophy: a multicenter case series.在接受onasemnogene abeparvovec治疗的脊髓性肌萎缩症患者中使用利司扑兰治疗:一项多中心病例系列研究
BMC Neurol. 2025 Jul 7;25(1):283. doi: 10.1186/s12883-025-04276-4.
5
Early Intervention and Speed-to-Effect in Spinal Muscular Atrophy Type 1 Following Onasemnogene Abeparvovec Gene Replacement Therapy: Results of aPost-Hoc Analysis of Pooled Clinical Study Data.1型脊髓性肌萎缩症经onasemnogene abeparvovec基因替代疗法后的早期干预与起效速度:汇总临床研究数据的事后分析结果
Neurol Ther. 2025 Jul 7. doi: 10.1007/s40120-025-00791-1.
6
Preliminary psychometric validation of patient-reported outcomes relevant to individuals with spinal muscular atrophy and their caregivers.与脊髓性肌萎缩症患者及其照料者相关的患者报告结局的初步心理测量学验证。
Orphanet J Rare Dis. 2025 Jun 4;20(1):274. doi: 10.1186/s13023-025-03832-y.
7
Cerebrospinal fluid biomarkers of efficacy in patients affected by spinal muscular atrophy type 1 treated with nusinersen.接受诺西那生治疗的1型脊髓性肌萎缩症患者疗效的脑脊液生物标志物
Acta Neurol Belg. 2025 May 3. doi: 10.1007/s13760-025-02784-1.
8
Rehabilitation improves the effectiveness of nusinersen in children with type 2 spinal muscular atrophy: pNF-H and muscle MRI as potential biomarkers.康复治疗可提高2型脊髓性肌萎缩症患儿使用诺西那生钠的疗效:磷酸化神经丝蛋白重链和肌肉磁共振成像作为潜在生物标志物
Front Neurol. 2025 Apr 11;16:1549587. doi: 10.3389/fneur.2025.1549587. eCollection 2025.
9
What did we learn from new treatments in SMA? A narrative review.我们从脊髓性肌萎缩症的新疗法中学到了什么?一篇叙述性综述。
Acta Myol. 2025 Mar;44(1):28-32. doi: 10.36185/2532-1900-1043.
10
Administration practices of and adherence to nusinersen in children with spinal muscular atrophy: a multicenter disease registry study in China.脊髓性肌萎缩症患儿中诺西那生钠的给药实践与依从性:一项中国多中心疾病登记研究
BMC Pediatr. 2025 Mar 27;25(1):239. doi: 10.1186/s12887-024-05290-0.
J Child Neurol. 2007 Aug;22(8):974-8. doi: 10.1177/0883073807305670.
4
Spinal muscular atrophy: clinical classification and disease heterogeneity.脊髓性肌萎缩症:临床分类与疾病异质性
J Child Neurol. 2007 Aug;22(8):946-51. doi: 10.1177/0883073807305673.
5
An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients.用于II型和III型脊髓性肌萎缩症患者的哈默史密斯功能运动量表扩展版。
Neuromuscul Disord. 2007 Oct;17(9-10):693-7. doi: 10.1016/j.nmd.2007.05.009. Epub 2007 Jul 19.
6
Therapeutics development for spinal muscular atrophy.脊髓性肌萎缩症的治疗研发
NeuroRx. 2006 Apr;3(2):235-45. doi: 10.1016/j.nurx.2006.01.010.
7
Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy.基于实时荧光定量PCR的SMN1和SMN2定量分析:脊髓性肌萎缩症携带者的快速、高度可靠检测及严重程度预测
Am J Hum Genet. 2002 Feb;70(2):358-68. doi: 10.1086/338627. Epub 2001 Dec 21.
8
Spinal muscular atrophy. Incidence in Iceland.脊髓性肌萎缩症。冰岛的发病率。
Neuroepidemiology. 1999;18(5):265-9. doi: 10.1159/000026221.
9
A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2.一个改变剪接模式的单核苷酸差异,将脊髓性肌萎缩症基因SMN1与复制基因SMN2区分开来。
Hum Mol Genet. 1999 Jul;8(7):1177-83. doi: 10.1093/hmg/8.7.1177.
10
A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients.一项关于儿童及青少年期起病的近端脊髓性肌萎缩症(II型和III型SMA)自然病史的合作研究:569例患者。
J Neurol Sci. 1997 Feb 27;146(1):67-72. doi: 10.1016/s0022-510x(96)00284-5.